Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.84 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.84 |
| ▸ | KIT known ✓ | P10721 | 11/20 | 0.84 |
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.84 |
| ▸ | LYN | P07948 | 2/20 | 0.84 |
| ▸ | EGFR | P00533 | 2/20 | 0.84 |
| ▸ | ABL2 | P42684 | 2/20 | 0.84 |
| ▸ | PLK4 | O00444 | 1/20 | 0.84 |
| ▸ | DDX3X | O00571 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.84 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.84 |
| ▸ | CA12 | O43570 | 1/20 | 0.84 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | CA1 | P00915 | 1/20 | 0.84 |
| ▸ | CA2 | P00918 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | ALB | P02768 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29355523 | 0.92 | ABL1 (1.00) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL2236091 | 0.92 | ABL1 (1.00) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL3827 | 0.92 | ABL1 (1.00) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL29351601 | 0.92 | ABL1 (1.00) | ABL1BCRKITPDGFRAPDGFRB | |
| SCHEMBL31553098 | 0.91 | ABL1 (0.94) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL15201213 | 0.91 | ABL1 (0.98) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL1462774 | 0.91 | ABL1 (0.98) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL16431247 | 0.91 | ABL1 (0.98) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL529425 | 0.91 | ABL1 (0.98) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL2929858 | 0.91 | ABL1 (0.98) | ABL1BCRKITPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240194469-A1 | MASS SPECTROMETRY ANALYSIS OF MICROORGANISMS IN SAMPLES | PURDUE RESEARCH FOUNDATION | 2024-06-13 | — | — | US | disclosed |
| US-11913924-B2 | Ion generation using modified wetted porous materials | PURDUE RESEARCH FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11867684-B2 | Sample dispenser including an internal standard and methods of use thereof | PURDUE RESEARCH FOUNDATION (US) | 2024-01-09 | — | — | US | disclosed |
| US-11830716-B2 | Mass spectrometry analysis of microorganisms in samples | PURDUE RESEARCH FOUNDATION (US) | 2023-11-28 | — | — | US | disclosed |
| CN-117110482-A | Method for detecting concentration of various CML targeted therapeutic drugs and application | 南昌大学第二附属医院 | 2023-11-24 | — | — | CN | disclosed |
| US-20230341360-A1 | ION GENERATION USING MODIFIED WETTED POROUS MATERIALS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-26 | — | — | US | disclosed |
| US-20230154737-A1 | MASS SPECTROMETRY ANALYSIS OF MICROORGANISMS IN SAMPLES | PURDUE RESEARCH FOUNDATION | 2023-05-18 | — | — | US | disclosed |
| US-11635415-B2 | Ion generation using modified wetted porous materials | PURDUE RESEARCH FOUNDATION (US) | 2023-04-25 | — | — | US | disclosed |
| EP-4152360-A1 | ION GENERATION USING WETTED POROUS MATERIAL | Purdue Research Foundation (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-3633710-B1 | ION GENERATION USING WETTED POROUS MATERIAL | PURDUE RESEARCH FOUNDATION (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4099363-A1 | MASS SPECTROMETRY ANALYSIS OF MICROORGANISMS IN SAMPLES | Purdue Research Foundation (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3486937-B1 | MASS SPECTROMETRY ANALYSIS OF MICROORGANISMS IN SAMPLES | PURDUE RESEARCH FOUNDATION (US) | 2022-07-27 | — | — | EP | disclosed |
| US-11393668-B2 | Mass spectrometry analysis of microorganisms in samples | PURDUE RESEARCH FOUNDATION (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220221442-A1 | SAMPLE DISPENSER INCLUDING AN INTERNAL STANDARD AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2022-07-14 | — | — | US | disclosed |
| US-20220133679-A1 | EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME | IZUMI TECHNOLOGY, LLC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11287414-B2 | Sample dispenser including an internal standard and methods of use thereof | PURDUE RESEARCH FOUNDATION (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220028674-A1 | ION GENERATION USING MODIFIED WETTED POROUS MATERIALS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133679-A1 | EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME | ABCB11, ABCB1, ABCC1 | ABL1 1431/4885BCR 118/4885KIT 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.